ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 134,94
-0,24%
Dow Jones
43 428,02
0,00%
DAX
22 480,41
0,97%
Brent Oil
74,015
-0,12%
Bitcoin
95 814,92
-0,48%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aquestive Therapeutics Inc (AQST)

  7. Aquestive Therapeutics Inc (AQST) Actualités

AQST

Aquestive Therapeutics (AQST)

Aquestive Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AQST
DateHeureSourceTitreSymboleSociété
20/02/202513h00GlobeNewswire Inc.Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
15/02/202500h12Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AQSTAquestive Therapeutics Inc
12/02/202513h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AQSTAquestive Therapeutics Inc
12/02/202513h00GlobeNewswire Inc.Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual MeetingNASDAQ:AQSTAquestive Therapeutics Inc
04/02/202513h00GlobeNewswire Inc.Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare ConferenceNASDAQ:AQSTAquestive Therapeutics Inc
24/01/202522h51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AQSTAquestive Therapeutics Inc
13/01/202513h00GlobeNewswire Inc.Aquestive Therapeutics Provides Business Update and Outlines Key 2025 ObjectivesNASDAQ:AQSTAquestive Therapeutics Inc
19/12/202414h00GlobeNewswire Inc.Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to FiveNASDAQ:AQSTAquestive Therapeutics Inc
02/12/202414h00GlobeNewswire Inc.Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
27/11/202422h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AQSTAquestive Therapeutics Inc
14/11/202421h47Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AQSTAquestive Therapeutics Inc
12/11/202414h00GlobeNewswire Inc.Aquestive Therapeutics to Participate in Two Upcoming Investor ConferencesNASDAQ:AQSTAquestive Therapeutics Inc
08/11/202423h31Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AQSTAquestive Therapeutics Inc
04/11/202422h36GlobeNewswire Inc.Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
25/10/202414h00GlobeNewswire Inc.Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American CollegeNASDAQ:AQSTAquestive Therapeutics Inc
24/10/202414h00GlobeNewswire Inc.Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
21/10/202414h00GlobeNewswire Inc.Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
02/10/202420h16Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AQSTAquestive Therapeutics Inc
27/09/202414h30GlobeNewswire Inc.Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor DayNASDAQ:AQSTAquestive Therapeutics Inc
09/09/202414h15GlobeNewswire Inc.Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27thNASDAQ:AQSTAquestive Therapeutics Inc
14/08/202414h00GlobeNewswire Inc.Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™NASDAQ:AQSTAquestive Therapeutics Inc
06/08/202422h26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AQSTAquestive Therapeutics Inc
06/08/202422h22GlobeNewswire Inc.Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
25/07/202414h00GlobeNewswire Inc.Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration StudyNASDAQ:AQSTAquestive Therapeutics Inc
23/07/202414h00GlobeNewswire Inc.Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
27/06/202414h00GlobeNewswire Inc.Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and MetabolismNASDAQ:AQSTAquestive Therapeutics Inc
25/06/202414h00GlobeNewswire Inc.Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
18/06/202414h00GlobeNewswire Inc.Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024NASDAQ:AQSTAquestive Therapeutics Inc
12/06/202423h14Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:AQSTAquestive Therapeutics Inc
11/06/202418h35Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AQSTAquestive Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AQST

Dernières Valeurs Consultées

NASDAQ
NVDA
NVIDIA
COIN
ETHUSD
Ethereum
EU
AI
Air Liquide
NYSE
KO
Coca Cola
EU
BN
Danone
EU
GLE
Societe Generale
EU
BEL20
Bel 20
NYSE
NKE
Nike
NASDAQ
AAPL
Apple
EU
RNO
Renault
EU
VK
Vallourec
EU
PX4
SBF 120
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces